Showing 2571-2580 of 4166 results for "".
- Staar Surgical Announces the EVO Implantable Lens US Clinical Trial is Underwayhttps://modernod.com/news/staar-surgical-announces-the-evo-implantable-lens-us-clinical-trial-is-underway/2477273/Staar Surgical announced the first patient was implanted in the company’s US human clinical study for its EVO ICL family of lenses. The investigational study, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens,” will be conducted at more than a dozen ophthalmology
- TECLens Announces Completion of Enrollment of a Pilot Clinical Study for the Treatment of Keratoconushttps://modernod.com/news/teclens-announces-completion-of-enrollment-of-a-pilot-clinical-study-for-the-treatment-of-keratoconus/2476980/TECLens announced the completion of enrollment of its pilot clinical study for the treatment of Keratoconus using the TECLens’ CXLens ‘on-eye’ cross-linking system for corneal remodeling. Clinical trial results are anticipated in early 2020. TECLens’ CXLens will pro
- Staar Surgical Announces Submission of Presbyopia Clinical Trial Datahttps://modernod.com/news/staar-surgical-announces-submission-of-presbyopia-clinical-trial-data/2479554/Staar Surgical announced the submission of its multisite European pivotal clinical trial data for the EVO+ Visian ICL with Aspheric (EDOF) Optic, a lens that is designed to provide correction or reduction of myopia or hyperopia and presbyopia. Results from the clinical trial were submitted to DEK
- Aura Biosciences to Present Long-Term Clinical Data for AU-011 at ASRShttps://modernod.com/news/aura-biosciences-to-present-long-term-clinical-data-for-au-011-at-asrs/2476767/Aura Biosciences announced that 2-year clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the Am
- ReNeuron Announces Retinal Clinical Trial Progresses to Next Stagehttps://modernod.com/news/reneuron-announces-retinal-clinical-trial-progresses-to-next-stage/2476391/ReNeuron Group has announced a further update on progress with the ongoing phase 1/2 clinical trial in the US of its hRPC cell therapy candidate in retinitis pigmentosa (RP). The company reported that, following a positive Data Safety Monitoring Board (DSMB) review of the clinical data fro
- Bausch + Lomb Initiates Clinical Trial Evaluating New Ophthalmic Viscosurgical Devicehttps://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-ophthalmic-viscosurgical-device/2480163/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new ophthalmic viscosurgical device (OVD). Bausch + Lomb aims to file for premarket approval (PMA) with the FDA at the conclusion of the clinical trial, with plans to bring this next-generation
- Isarna Therapeutics Announces Phase 2 Clinical Data Presentations at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/isarna-therapeutics-announces-phase-2-clinical-data-presentations-at-upcoming-ophthalmology-conferences/2482263/Isarna Therapeutics announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4 and the Association for Research in Vision and Ophthalmology (ARVO) meeting on May 7, both in Seattle. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, will present upd
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Bascom Palmer Treats First US Patient in Nightstar Gene Therapy Clinical Trial for X-Linked Retinitis Pigmentosahttps://modernod.com/news/bascom-palmer-treats-first-us-patient-in-nightstar-gene-therapy-clinical-trial-for-x-linked-retinitis-pigmentosa/2479869/A patient with X-linked retinitis pigmentosa (XLRP) is hoping to save his vision after an innovative gene therapy procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. On August 23, Julio Adorno Nieves, 23, of Puerto Rico, became the first U.S. patient to
- Ocumension Obtains Positive Phase 3 Clinical Trial Results for Zerviate in Chinahttps://modernod.com/news/nicoxs-partner-ocumension-obtains-positive-phase-3-clinical-trial-results-for-zerviate-in-china/2480670/Nicox announced positive results in a Chinese phase 3 clinical trial of Zerviate (cetirizine ophthalmic solution), 0.24%, run by its partner, Ocumension Therapeutics.